OPR - Delayed Quote • USD REGN Jan 2026 750.000 call (REGN260116C00750000) Follow 258.87 0.00 (0.00%) As of January 2 at 1:04 PM EST. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for REGN260116C00750000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: REGN Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma EXEL vs. REGN: Which Stock Is the Better Value Option? Regeneron (REGN) Reports Next Week: What You Should Expect UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Regeneron expands in gene editing with Mammoth deal Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
